Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Current Leases (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Current Leases for 7 consecutive years, with $11.9 million as the latest value for Q4 2025.

  • Quarterly Current Leases rose 686.63% to $11.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.9 million through Dec 2025, up 686.63% year-over-year, with the annual reading at $11.9 million for FY2025, 686.63% up from the prior year.
  • Current Leases for Q4 2025 was $11.9 million at Kymera Therapeutics, up from $1.9 million in the prior quarter.
  • The five-year high for Current Leases was $11.9 million in Q4 2025, with the low at $640000.0 in Q1 2021.
  • Average Current Leases over 5 years is $2.5 million, with a median of $1.3 million recorded in 2023.
  • The sharpest move saw Current Leases plummeted 55.64% in 2024, then skyrocketed 930.98% in 2025.
  • Over 5 years, Current Leases stood at $1.1 million in 2021, then increased by 23.73% to $1.4 million in 2022, then decreased by 9.3% to $1.3 million in 2023, then increased by 18.87% to $1.5 million in 2024, then skyrocketed by 686.63% to $11.9 million in 2025.
  • According to Business Quant data, Current Leases over the past three periods came in at $11.9 million, $1.9 million, and $1.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.